{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:54:37Z","timestamp":1790679277481,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.ymgme.2010.03.020","type":"journal-article","created":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T04:35:09Z","timestamp":1270182909000},"page":"257-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Plasma globotriaosylsphingosine as a biomarker of Fabry disease"],"prefix":"10.1016","volume":"100","author":[{"given":"Tadayasu","family":"Togawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2010.03.020_bib1","unstructured":"R.J. Desnick, Y.A. Ioannou, C.M. Eng, \u03b1-Galactosidase A deficiency: Fabry disease, in: C.R. Scriver, W.A. Sly, A.L. Beaudet, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, eighth ed., McGraw-Hill Inc., New York, 2001, pp. 3733\u20133774."},{"key":"10.1016\/j.ymgme.2010.03.020_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2010.03.020_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2010.03.020_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2010.03.020_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2010.03.020_bib6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2010.03.020_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2010.03.020_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2010.03.020_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease \u2014 role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2010.03.020_bib10","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-008-0846-6","article-title":"Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes","volume":"23","author":"Kitagawa","year":"2008","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2010.03.020_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cca.2009.02.016","article-title":"An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring","volume":"403","author":"Rozenfeld","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2010.03.020_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Pediatr."},{"key":"10.1016\/j.ymgme.2010.03.020_bib13","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2010.03.020_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","article-title":"Molecular interaction of imino sugars with human \u03b1-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease","volume":"96","author":"Sugawara","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2010.03.020_bib15","unstructured":"W.L. Hwu, Y.H. Chien, N.C. Lee, S.C. Chiang, R. Dobrovolny, A.C. Huang, H.Y. Yeh, M.C. Chao, S.J. Lin, T. Kitagawa, R.J. Desnick, L.W. Hsu, Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A), Hum. Mutat., doi: 10.1002\/humu. 21074."},{"key":"10.1016\/j.ymgme.2010.03.020_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2010.03.020_bib17","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2010.03.020_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2010.03.020_bib19","first-page":"c33","article-title":"Fabry disease in patients with end-stage renal failure: the potential benefits of screening","volume":"101","author":"Bekri","year":"2005","journal-title":"Nephron"},{"key":"10.1016\/j.ymgme.2010.03.020_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2010.03.020_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2010.03.020_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1022436928925","article-title":"Twenty-five years of the \u201cpsychosine hypothesis\u201d: a personal perspective of its history and present status","volume":"23","author":"Suzuki","year":"1988","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymgme.2010.03.020_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2010.03.020_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0005-2760(82)90272-7","article-title":"The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher\u2019s disease","volume":"712","author":"Nilsson","year":"1982","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2010.03.020_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-4684-7735-1_8","article-title":"Chemical pathology of Krabbe disease: the occurrence of psychosine and other neutral sphingolipids","volume":"68","author":"Vanier","year":"1976","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgme.2010.03.020_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0021-9258(18)69582-1","article-title":"The enzymatic synthesis of psychosine","volume":"235","author":"Cleland","year":"1960","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2010.03.020_bib27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1471-4159.1992.tb08460.x","article-title":"Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses","volume":"59","author":"Kobayashi","year":"1992","journal-title":"J. Neurochem."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:18:14Z","timestamp":1761088694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719210001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1096719210001393"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.020","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}